Moreover, blocking CD36 in patient-derived prostate cancer xenograft (PDX) models reduces tumor growth in CD36high PDX models, suggesting a potential therapeutic benefit of blocking fatty acid uptake in CD36high prostate cancer [64]. The gene discussed is CD36; the disease is prostate carcinoma.